Breaking The AAV Titer Barrier: A 9x Manufacturing Breakthrough

Increasing AAV yield without compromising product quality requires careful optimization across the production workflow. Customer data from a collaboration with MicroBiopharm Japan demonstrates how targeted adjustments to cell culture media and transfection reagents increased AAV titers ninefold. The findings offer practical guidance for strengthening HEK293-based production, including approaches to improve full capsid percentages and build greater process robustness. By examining how media conditions and transfection performance work together, gene therapy developers and manufacturers can identify opportunities to improve output while supporting consistent quality.

Explore a collaborative, data-driven strategy for resolving production bottlenecks and accelerating AAV process development in a rapidly evolving market.